tuneTypical Dose
18–24 IU acute. 24 IU BID in common ASD trial paradigms. 48 IU/day in larger ASD trial.
Peptide
Oxytocin
Oxytocin
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Acute task effects can appear within ~1 hour. Sustained clinical outcomes are inconsistent across trials.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Oxytocin is a peptide hormone involved in social bonding, stress responses, childbirth, and lactation. It is studied for social cognition effects, commonly via intranasal administration in research settings.
Research on intranasal oxytocin shows mixed results for improving social cognition in autism and schizophrenia, with effects dependent on context and individual traits. Some studies suggest reduced stress reactivity and improved specific interpersonal behaviors. Minority evidence explores postpartum bonding and sexual function outcomes. Overall benefits are heterogeneous and not consistently replicated across trials.
OXT signaling through oxytocin receptors appears to modulate social salience and affiliative behavior in task-specific contexts. Clinical effects are mixed and protocol-sensitive.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Social affiliative behavior
- Social cognition
- Social reciprocity
Secondary Outcomes
- Social performance under pressure
- Stress reactivity (cortisol)
Safety
Contraindications and Interactions
Contraindications
- Pregnancy
- Breastfeeding
- Active psychosis/mania
- Severe cardiovascular instability
- Severe uncontrolled endocrine disorder
Side effects
- Nasal irritation
- Headache
- Nausea
Interactions
- Sedatives or psychoactive agents
- Hormone-modulating compounds
Avoid if
- Children without specialist protocol
- Unsupervised stacking
- Severe psychiatric instability
Evidence
Study-level References
oxytocin-SRC-001Randomized, placebo-controlled behavioral trial
Sourceopen_in_newKosfeld et al. 2005. "Oxytocin increases trust in humans." Nature 435: 673–676. doi:10.1038/nature03701.
Population: Healthy adults
Dose protocol: Intranasal administration (single-dose oxytocin vs placebo, task-linked social decision paradigm)
Key findings: Acute, context-bound increase in trust-linked decision behavior.
Notes: Strong classic mechanistic/behavioral signal. Does not establish clinical disorder treatment effect.
Paper content
Acute, context-bound increase in trust-linked decision behavior.
oxytocin-SRC-002Randomized, placebo-controlled protocol study
Sourceopen_in_newGuastella et al. 2009. Adjunct intranasal oxytocin in social anxiety exposure therapy. Psychoneuroendocrinology.
Population: Adults with social anxiety disorder (small sample)
Dose protocol: 24 IU intranasal administered with exposure therapy sessions
Key findings: Some improvement in task-specific social perception metrics. No broad treatment-effect superiority in overall outcome scales.
Notes: Important for context-dependent, adjunctive interpretation.
Paper content
Some improvement in task-specific social perception metrics; no broad treatment-effect superiority in overall outcome scales.
oxytocin-SRC-003Randomized, double-blind, placebo-controlled pilot trial
Sourceopen_in_newAnagnostou et al. 2012. "Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders." Mol Autism 3: 16.
Population: Adults with ASD
Dose protocol: 24 IU intranasal, twice daily for 6 weeks
Key findings: Some secondary social cognition improvements, no robust primary outcomes in a small sample.
Notes: Suggests biological plausibility with high uncertainty and placebo expectancy confounding.
Paper content
Some secondary social cognition improvements, no robust primary outcomes in a small sample.
oxytocin-SRC-004Randomized, double-blind, placebo-controlled multicenter trial
Sourceopen_in_newYamasue et al. 2018. "Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: randomized clinical trial." Molecular Psychiatry 25: 1849–1858.
Population: Adults with ASD
Dose protocol: 48 IU/day for 6 weeks
Key findings: No significant between-group difference in ADOS primary reciprocity. Secondary repetitive behavior and gaze metrics showed some signal.
Notes: High-quality larger RCT with nuanced interpretation: not ready for generalized clinical recommendation at tested dose/duration.
Paper content
No significant between-group difference in ADOS primary reciprocity; secondary repetitive behavior and gaze metrics showed some signal.
oxytocin-SRC-005Randomized, double-blind, placebo-controlled, long-duration trial
Sourceopen_in_newSikich et al. 2021. "Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder." N Engl J Med 385(16): 1462-1473. doi:10.1056/NEJMoa2103583.
Population: Children and adolescents with ASD
Dose protocol: target 48 IU/day intranasal, with longer multi-week protocol and optional escalation
Key findings: No significant treatment-placebo difference on primary and most secondary social outcomes.
Notes: Largest controlled pediatric dataset in the area to date. Informs conservative interpretation.
Paper content
No significant treatment-placebo difference on primary and most secondary social outcomes.
oxytocin-SRC-006Safety review/synthesis
Sourceopen_in_newMacDonald et al. 2011. "A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research." Psychoneuroendocrinology 36(8): 1114-1126. doi:10.1016/j.psyneuen.2011.02.015.
Population: Adults in controlled research settings (N=1529 in reported trials)
Dose protocol: 18–40 IU short-term dosing predominated
Key findings: Short-term controlled use generally did not show reliable increases in adverse events versus placebo.
Notes: Does not replace long-term safety requirements.
Paper content
Short-term controlled use generally did not show reliable increases in adverse events versus placebo.
oxytocin-SRC-007Meta-analysis
Sourceopen_in_newCardoso et al. 2014. "A meta-analytic review of the impact of intranasal oxytocin administration on cortisol concentrations during laboratory tasks." Psychoneuroendocrinology 49: 161–170. doi:10.1016/j.psyneuen.2014.07.014.
Population: Healthy adults and clinical samples
Dose protocol: Acute task-based intranasal dosing
Key findings: Modest/no robust overall cortisol attenuation. Stronger effects only in high-stress protocols and some clinical subgroups.
Notes: Supports caution in over-claiming broad stress-damping effects.
Paper content
Modest/no robust overall cortisol attenuation; stronger effects only in high-stress protocols and some clinical subgroups.
oxytocin-SRC-008Regulatory documentation
Sourceopen_in_newFDA label lineage for injectable oxytocin (e.g., oxytocin injection, IV/IM/SQ indications); intranasal formulations for social/psychiatric indications are not the primary approved indication.
Population: Clinical obstetric use
Dose protocol: Obstetric IV/IM/SQ dosing
Key findings: Supports Rx-only status and route-specific approved use. Non-obstetric use remains off-label/research pathway.
Notes: Keep wording jurisdiction-specific in final product guidance.
Paper content
Supports Rx-only status and route-specific approved use; non-obstetric use remains off-label/research pathway.
oxytocin-SRC-009Systematic review.
Sourceopen_in_newBarton S, Pruin A, Schulze J, Kiebs M, Scheele D, Hurlemann R. Dose-response effects of exogenous oxytocin on social cognition: A systematic review. Neurosci Biobehav Rev. 2025;178:106350. doi:10.1016/j.neubiorev.2025.106350. PMID:40882784.
Population: Human studies using intranasal oxytocin across dose ranges of 1 to 48 IU.
Dose protocol: Systematic review of intranasal oxytocin 1 to 48 IU across included studies
Key findings: Standard 24 IU dose generally improved emotion recognition, empathy, and trust. Inverted-U dose-response hypothesis lacks direct dose-comparison evidence. Effects are strongly moderated by individual and contextual factors.
Notes: Most comprehensive dose-response review to date.
Paper content
This systematic review examined dose-response effects of intranasal oxytocin on social cognition across studies using 1 to 48 IU. At the standard 24 IU dose, most studies found improvements in emotion recognition, empathy, and trust. However, the review found that evidence supporting the inverted-U dose-response hypothesis is limited because few studies directly compared multiple doses. The authors emphasized that effects appear strongly moderated by individual and contextual factors, questioning the generalizability of any single-dose recommendation.